

Bullous pemphigoid - Pipeline Insight, 2021

<https://marketpublishers.com/r/B37E98497113EN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: B37E98497113EN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Bullous pemphigoid - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Bullous pemphigoid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Bullous pemphigoid Understanding

Bullous pemphigoid: Overview

Bullous pemphigoid (BP) is a rare, autoimmune, chronic skin disorder characterized by blistering, urticarial lesions (hives) and itching. Less commonly these blisters can involve the mucous membranes including the eyes, oral mucosa, esophagus and genital mucosa. It typically presents in older adults as a generalized intensely itchy blistering skin condition. The first symptom of BP is usually redness and itching of the skin. Within weeks to months, thin-walled, tense blisters with clear fluid centers (bullae) appear on the arms and legs (flexor surfaces), in the armpits (axillae), on the abdomen, and/or in the skinfolds of the groin. Mucous membranes may also be involved but are less commonly seen than skin blisters.

'Bullous pemphigoid - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bullous pemphigoid pipeline landscape is provided which includes the disease overview and Bullous pemphigoid treatment guidelines. The assessment part of the report embraces, in depth Bullous pemphigoid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bullous pemphigoid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bullous pemphigoid R&D. The therapies under development are focused on novel approaches to treat/improve Bullous pemphigoid.

Bullous pemphigoid Emerging Drugs Chapters

This segment of the Bullous pemphigoid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bullous pemphigoid Emerging Drugs

Benralizumab: AstraZeneca

Interleukin-5 (IL-5) induces an eosinophil-mediated inflammatory response by binding to the IL-5 receptor (IL-5R) expressed in eosinophils, basophils and some mast cells. Benralizumab, unlike IL-5 low-affinity binding, binds with high affinity to the domain I of the α -chain of IL-5R and blocks its signaling and the proliferation of IL-5-dependent cell lines. On the other hand, Benralizumab is an afucosylated antibody in the CH2 region which gives it a high affinity for the Fc γ R1IIa on natural killer cells, macrophages and neutrophils. This binding triggers a magnified apoptosis response in eosinophils via antibody-dependent cell-mediated cytotoxicity. Currently, it is in Phase III stage of

clinical trial evaluation to treat Bullous Pemphigoid.

Dupilumab: Regeneron/Sanofi

Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor ? (IL-4R?) that inhibits both IL-4 and IL-13 signaling. Dupilumab (Dupixent) is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. The drug is in Phase III clinical studies for Bullous Pemphigoid. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. Dupilumab was invented using Regeneron's proprietary VelocImmune technology. The FDA has granted orphan drug designation to Dupilumab for the treatment of Bullous Pemphigoid.

Further product details are provided in the report.....

Bullous pemphigoid: Therapeutic Assessment

This segment of the report provides insights about the different Bullous pemphigoid drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Bullous pemphigoid

There are approx. 8+ key companies which are developing the therapies for Bullous pemphigoid. The companies which have their Bullous pemphigoid drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Bullous pemphigoid pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bullous pemphigoid: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bullous pemphigoid therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bullous pemphigoid drugs.

Bullous pemphigoid Report Insights

Bullous pemphigoid Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Bullous pemphigoid Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Bullous pemphigoid drugs?

How many Bullous pemphigoid drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bullous pemphigoid?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bullous pemphigoid therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Bullous pemphigoid and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AstraZeneca

Regeneron

Alkahest

Akari Therapeutics

Immune Pharmaceuticals

Eli Lilly and Company

Amgen

TWi Biotechnology

Key Products

Benralizumab

Dupilumab

Lazucirnon

Nomacopan

Bertilimumab

Ixekizumab

Apremilast

Diacerein

Contents

Introduction

Executive Summary

Bullous pemphigoid: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Bullous pemphigoid – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Benralizumab: AstraZeneca

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Lazucirnon : Alkahest

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Sutimlimab: Bioverativ

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Bullous pemphigoid Key Companies

Bullous pemphigoid Key Products

Bullous pemphigoid- Unmet Needs

Bullous pemphigoid- Market Drivers and Barriers

Bullous pemphigoid- Future Perspectives and Conclusion

Bullous pemphigoid Analyst Views

Bullous pemphigoid Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Bullous pemphigoid

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Bullous pemphigoid

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Bullous pemphigoid - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/B37E98497113EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B37E98497113EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970